NCT02316509View on ClinicalTrials.gov

A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 17, 2015

Primary Completion Date

January 10, 2020

Study Completion Date

January 10, 2020

Conditions
Breast Cancer
Interventions
DRUG

GDC-0927

GDC-0927 will be administered as per schedule specified in the respective arm.

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

20014

Onkologikoa - Kutxaren Institutu Onkologikoa, Donostia / San Sebastian

28033

MD Anderson Cancer Center Madrid - España; Servicio de Farmacia, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28040

Hospital General Universitario Gregorio Maranon, Madrid

28050

HM Sanchinarro - CIOCC, Madrid

37232

Vanderbilt Ingram Cancer Ctr, Nashville

38138

Sarah Cannon Cancer Center, Germantown

46010

Hospital Clinico Universitario de Valencia, Valencia

02114

Massachusetts General Hospital., Boston

02215

Dana Farber Cancer Institute, Boston

08908

ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO, L'Hospitalet de Llobregat

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

Sponsors

Lead Sponsor

Genentech, Inc.

Collaborators (1)

Seragon Pharmaceuticals
All Listed Sponsors
collaborator

Seragon Pharmaceuticals

UNKNOWN

lead

Genentech, Inc.

INDUSTRY